Abstract:Tetraploid (4N) cells are considered important in cancer because they can display increased tumorigenicity, resistance to conventional therapies, and are believed to be precursors to whole chromosome aneuploidy. It is therefore important to determine how tetraploid cancer cells arise, and how to target them. P53 is a tumor suppressor protein and key regulator of tetraploidy. As part of the "tetraploidy checkpoint", p53 inhibits tetraploid cell proliferation by promoting a G1-arrest in incipient tetraploid cells (referred to as a tetraploid G1 arrest). Nutlin-3a is a preclinical drug that stabilizes p53 by blocking the interaction between p53 and MDM2. In the current study, Nutlin-3a promoted a p53-dependent tetraploid G1 arrest in two diploid clones of the HCT116 colon cancer cell line. Both clones underwent endoreduplication after Nutlin removal, giving rise to stable tetraploid clones that showed increased resistance to ionizing radiation (IR) and cisplatin (CP)-induced apoptosis compared to their diploid precursors. These findings demonstrate that transient p53 activation by Nutlin can promote tetraploid cell formation from diploid precursors, and the resulting tetraploid cells are therapy (IR/CP) resistant. Importantly, the tetraploid clones selected after Nutlin treatment expressed approximately twice as much P53 and MDM2 mRNA as diploid precursors, expressed approximately twice as many p53-MDM2 protein complexes (by co-immunoprecipitation), and were more susceptible to p53-dependent apoptosis and growth arrest induced by Nutlin. Based on these findings, we propose that p53 plays novel roles in both the formation and targeting of tetraploid cells. Specifically, we propose that 1) transient p53 activation can promote a tetraploid-G1 arrest and, as a result, may inadvertently promote formation of therapy-resistant tetraploid cells, and 2) therapy-resistant tetraploid cells, by virtue of having higher P53 gene copy number and expressing twice as many p53-MDM2 complexes, are more sensitive to apoptosis and/or growth arrest by anti-cancer MDM2 antagonists (e.g. Nutlin).

Targeting P53 for Novel Anticancer Therapy.

Small Molecule Agents Targeting the P53-Mdm2 Pathway for Cancer Therapy

Current strategies to target p53 in cancer.

Targeting mutant p53 for cancer therapy: direct and indirect strategies

Targeting p53 pathways: mechanisms, structures, and advances in therapy

Translating p53-based therapies for cancer into the clinic

The Development of P53-Targeted Therapies for Human Cancers

Restoration of p53 to limit tumor growth

Anticancer therapeutic strategies for targeting mutant p53-Y220C

Targeting mutant p53 for efficient cancer therapy

Therapeutic targeting of p53 by small molecules

Resuscitating the Guardian: Current Progress in P53-Based Anti-Tumor Therapy

Towards the Overcoming of Anticancer Drug Resistance Mediated by P53 Mutations

Small-Molecule Inhibitors of the MDM2-p53 Protein-Protein Interaction to Reactivate p53 Function: A Novel Approach for Cancer Therapy

p53's Multifaceted Role in the DNA Damage Response and Tumor Treatment Strategies

Targeting mutant p53 stabilization for cancer therapy

Small-Molecule Modulators Of P53 Family Signaling And Antitumor Effects In P53-Deficient Human Colon Tumor Xenografts

Restoring the Tumour Suppressive Function of P53 As a Parallel Strategy in Melanoma Therapy

Restoring p53 function in cancer: novel therapeutic approaches for applying the brakes to tumorigenesis

Small Molecule Inhibitors of the P53-Mdm2

Novel Roles For P53 In The Genesis And Targeting Of Tetraploid Cancer Cells